CLAIMS

1. A crystalline form of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.

2. A crystalline Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.

3. The crystalline form according to claims 1 or 2 characterized by having an x-ray powder diffraction pattern comprising reflections at 2-Theta angles of 4.5 ± 0.2°, 9.0 ± 0.2° and 16.6 ± 0.2°, when measured with Cu-Kalpha radiation.

4. The crystalline form according to claims 1 to 3, characterized by having an x-ray powder diffraction pattern comprises reflections at 2-Theta angles of 4.5 ± 0.2°, 9.0 ± 0.2°, 16.6 ± 0.2°, 21.1 ± 0.2° and 25.3 ± 0.2° when measured with Cu-Kalpha radiation.

5. A crystalline Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol characterized by having an x-ray powder diffraction pattern comprising three, four, five or more 2 theta values selected from the group consisting of 4.5 ± 0.2°, 8.1 ± 0.2°, 9.0 ± 0.2°, 11.9 ± 0.2°, 12.2 ± 0.2°, 13.2 ± 0.2°, 13.5 ± 0.2°, 14.2 ± 0.2°, 14.6 ± 0.2°, 15.0 ± 0.2°, 15.3 ± 0.2°, 15.7 ± 0.2°, 16.6 ± 0.2°, 17.0 ± 0.2°, 17.2 ± 0.2°, 17.7 ± 0.2°, 18.0 ± 0.2°, 19.0 ± 0.2°, 19.8 ± 0.2°, 20.0 ± 0.2°, 20.2 ± 0.2°, 20.4 ± 0.2°, 21.1 ± 0.2°, 22.8 ± 0.2°, 23.3 ± 0.2°, 23.8 ± 0.2°, 24.3 ± 0.2°, 24.9 ± 0.2°, 25.3 ± 0.2°, 25.8 ± 0.2°, 26.3 ± 0.2°, 27.1 ± 0.2°, 27.3 ± 0.2°, 27.7 ± 0.2°, 28.0 ± 0.2°, and 28.4 ± 0.2°, when measured with Cu-Kalpha radiation.

6. A crystalline Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol characterized by the x-ray powder diffraction pattern shown in FIG. 1.

7. The crystalline form according to any one of claims 1 to 6 characterized by having endothermic events at about 193°C and at about 261°C in differential scanning calorimetry (DSC) thermogram profile.

8. The crystalline form according to any one of claims 1 to 7 characterized by having a thermogravimetry coupled fourier transform infrared (TG-FTIR) spectroscopy thermogram showing decomposition occurring at temperatures of about 270°C.

9. The crystalline form according to any one of claims 1 to 8 characterized by having an FT-RAMAN spectrum at least one, more preferably at least two, still more preferably at least four, and most preferably all, of the RAMAN bands at about 3123, 3107, 3075, 2974, 1620, 1610, 1590, 1458, 1397, 1377, 1335, 1319, 1305, 1291, 1266, 1259, 1230, 1188, 1166, 1138, 1126, 1082, 1064, 1028, 971, 960, 900, 827, 770, 742, 713, 625, 580, 550, 531, 446, 377, 345, 330, 256, 241, 180, 163, 141, 108, 101 cm −1.

10. A crystalline Form B of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.

11. The crystalline form according to claims 1 and 10 characterized by having an x-ray powder diffraction pattern comprising reflections at 2-Theta angles of 5.2 ± 0.2°, 6.0 ± 0.2° and 15.8 ± 0.2°, when measured with Cu-Kalpha radiation.

12. The crystalline form according to claims 1, 10, and 11, characterized by having an x-ray powder diffraction pattern comprises reflections at 2-Theta angles of 5.2 ± 0.2°, 6.0 ± 0.2°, 10.5 ± 0.2°, 12.6 ± 0.2° and 15.8 ± 0.2°, when measured with Cu-Kalpha radiation.

13. A crystalline Form B of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol characterized by having an x-ray powder diffraction pattern comprising three, four, five or more 2 theta values selected from the group consisting of 5.2 ± 0.2°, 6.0 ± 0.2°, 8.7 ± 0.2°, 10.5 ± 0.2°, 12.0 ± 0.2°, 12.6 ± 0.2°, 12.9 ± 0.2°, 14.5 ± 0.2°, 14.8 ± 0.2°, 15.0 ± 0.2°, 15.8 ± 0.2°, 17.4 ± 0.2°, 17.6 ± 0.2°, 17.8 ± 0.2°, 18.0 ± 0.2°, 18.4 ± 0.2°, 19.0 ± 0.2°, 19.2 ± 0.2°, 19.9 ± 0.2°, 22.7 ± 0.2°, 23.3 ± 0.2°, 23.7 ± 0.2°, 24.0 ± 0.2°, 24.5 ± 0.2°, 25.0 ± 0.2°, 25.4 ± 0.2°, 25.8 ± 0.2°, 26.2 ± 0.2°, and 27.6 ± 0.2°, when measured with Cu-Kalpha radiation.

14. A crystalline Form B of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol characterized by the x-ray powder diffraction pattern shown in FIG. 5.

15. The crystalline form according to any one of claims 1, 10 to 14 characterized by having an endothermic event at about 260°C in differential scanning calorimetry (DSC) thermogram profile.

16. The crystalline form according to any one of claims 1, 10 to 15 characterized by having a thermogravimetry coupled fourier transform infrared (TG-FTIR) spectroscopy thermogram showing mass changes from about 25°C to about 140°C and from about 140°C to about 210°C.

17. The crystalline form according to any one of claims 1, 10 to 16 characterized by having an FT-RAMAN spectrum at least one, more preferably at least two, still more preferably at least four, and most preferably all, of the RAMAN bands at about 3145, 2974, 2931, 1629, 1611, 1462, 1401, 1376, 1340, 1325, 1307, 1295, 1271, 1215, 1164, 1058, 996, 900, 836, and 706 cm −1.

18. A pharmaceutical composition comprising a crystalline form of claims 1-17, and a pharmaceutically acceptable carrier.

19. A process for the preparation of crystalline Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol comprising: (a) dissolving 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol in N,N-dimethylformamide; (b) adding water; and optionally (c) isolating crystalline Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.

20. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a crystalline form of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol according to any one of Claims 1-19; and (b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.

21. The pharmaceutical composition of Claim 20, wherein the crystalline form is Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.

22. Use of a crystalline form of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol according to any one of Claims 1-17 or the pharmaceutical composition of claims 20-21 in the manufacture of a medicament for the treatment or amelioration of Huntington’s Disease, wherein a therapeutically effective amount of the medicament is to be administered to a subject in need thereof.

23. The use of claim 22, wherein the crystalline form is Form A of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol.